APAC Veterinary/Animal Vaccines Market Size & Growth (2019 - 2024)
The Asia Pacific animal vaccines market is poised to reach USD 1.53 Billion by 2024 from USD 1.08 Billion in 2019, at a CAGR of 7.22% from 2019 - 2024 and considered as the fastest-growing region in the global veterinary vaccines market.
Veterinary vaccines are mainly used to prevent transmission of diseases from animals to humans. These vaccines are specially manufactured to reduce or prevent contracting diseases. The main aim of veterinary vaccines is to promote good health and wellbeing of companion animals along with increasing production of poultry products with high quality.
Increasing prevalence for the production of quality products from the livestock population is a key driving factor for the market to grow. The rise in the incidences of various diseases like the zoonotic disease is accelerating the growth of the APAC veterinary vaccines market. People's concern towards animal health is growing eventually which is solely to boost the demand of the market. In addition, on-going research to introduce innovative drugs is leveraging the growth of the market.
However, the lack of skilled persons in developing various vaccines for different health disorders in animals is slowly hampering the growth of the market. Stringent rules and regulations by the government in approving new products are restraining the demand of the market. Also, increasing prices of treatment procedures in veterinary hospitals remains a challenging factor for the market growth in the Asia Pacific.
Growth opportunities for the market lie in the increasing awareness over the availability of various treatment procedures for different diseases in animals through campaigns and digital advertisements. An increasing number of veterinary hospitals and pharmaceutical industries are ascribed to outshine the growth rate of the market. Furthermore, the Veterinary vaccines market in the Asia Pacific is propelled by a rise in the demand to focus on immunization. Besides, shifting trend towards healthy lifestyles by maintaining a healthy diet with protein foods is likely to outshine the growth of the Veterinary/Animal vaccines market in the Asia Pacific.
This research report segmented and sub-segmented into the following categories:
Among all, the Indian Veterinary vaccines market is holding the highest shares of the market. Rising carious diseases in livestock are bolstering the demand of the market eventually. Also, growing awareness over the availability of different vaccines for various diseases is likely to magnify the demand of the market.
The Veterinary/Animal vaccine market in China is also accounted to have significant shares of the market following India. Increasing revenue is one of the best parts for China to have leading shares in this market. A rise in the adoption of companion animals is boosting up the growth rate of the market.
Japanese Veterinary Vaccines Market is witnessed in having the fastest growth rate form the past few years and is also expected to have the same growth flow in the coming years. Shifting to DNA vaccines rather than live attenuated vaccines will increase the performance levels in controlling the diseases and this is majorly considered as a growth factor for the market. Also, Adoption of recombinant vaccine solutions is fuelling the growth rate of the market in this country.
The market of veterinary vaccines in Australia is anticipated to have inclined growth rates in the coming years with rising awareness towards safety measurements for animal healthcare.
South Korean Veterinary Vaccine Market is deemed to have significant shares in the coming years by increasing investments from private and public organizations.
Prominent companies playing an active role in the Asia-Pacific Veterinary/Animal Vaccines Market are Bayer HealthCare AG, Bioniche Animal Health Canada, Sanofi Animal Health. Inc., Biogenesis Bago SA, Heska Corporation, Indian Immunologicals Ltd., Boehringer Ingelheim GmbH, Zoetis, Novartis Animal Health. Inc, Merck & Co. Inc and Protein Sciences.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Type
5.1.1 Livestock vaccines
5.1.2 Companion vaccines
5.2.1 Live attenuated vaccines
5.2.2 Inactivated vaccines
5.2.3 Recombinant vaccines
5.2.4 Toxoid vaccines
5.2.5 Subunit vaccines
5.2.6 DNA vaccines
5.2.7 Conjugate vaccines
6.5 South Korea
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Bayer Healthcare AG
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Bioniche Animal Health Canada
8.3 Sanofi Animal Health Inc.
8.4 Biogenesis Bago SA
8.5 Heska Corporation
8.6 Indian Immunologicals Ltd.
8.7 Boehringer Ingelheim GmbH
8.8 Novartis Animal Health, Inc.
8.9 Merck & Co. Inc.
8.10 Protein Sciences
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities